Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

HPV Infection May Be Linked To Poor Head And Neck Cancer Survival In African Americans
A groundbreaking study in Cancer Prevention Research, a journal of the American Association for Cancer Research, suggests that having the human papillomavirus (HPV) improves survival in squamous cell carcinoma of the head and neck. Furthermore, African Americans had far less HPV infection than whites, which led to worse survival.
new payday loan lenders
Buy zoloft and forget about depression.
Births To Unmarried Women Increasing In U.S., Driven By Women In 20s, 30s, Report Shows
Almost 40% of U.S. births in 2007 occurred among unmarried women, according to a report from the Centers for Disease Control and Prevention"s National Center for Health Statistics, the Washington Post reports. About 1.7 million infants were born to unmarried women in 2007, representing a 26% increase over the 1.4 million in 2002 and more than double the number in 1980. Unmarried women accounted for 39.7% of all U.S. births in 2007, up from 34% in 2002 and more than double the percentage in 1980, according to the report, which studied birth certificates nationwide.Women in their 20s and 30s are the biggest drivers of the trend, with out-of-wedlock births in this age group increasing from a rate of 13% to 34% between 2002 and 2006, according to the report (Stein/St. George, Washington Post, 5/14). For example, the birthrate for unmarried women ages 30 to 34 rose by 34% in 2007 compared with 2002 (Harris, New York Times, 5/14). Sixty percent of births to women ages 20 to 24 were to unmarried women, compared to 52% in 2002. In addition, 32% of births to women 25 to 29 were to unmarried women, compared to 25% in 2002, the report shows (Jayson, USA Today, 5/14). Overall, women in their 20s made up 60% of U.S. unmarried births in 2007, while teens accounted for 23% and women ages 30 and older accounted for 17% (New York Times, 5/13). Unmarried Hispanic women gave birth at a rate of 106 births per 1,000 unmarried women. The rate was 72 per 1,000 for blacks, 32 per 1,000 for whites and 26 per 1,000 for Asians. The rates for blacks and Hispanics rose the fastest, according to the report (Washington Post, 5/14). Compared with other countries, the U.S. rate of unmarried births was near the middle of the 14 countries included in the report (USA Today, 5/14).Although researchers did research the reasons for the trend, they cited several factors that in combination likely affected the rate, including a decrease in the social stigma surrounding out-of-wedlock births, an increasing number of couples putting off or forgoing marriage, and growing numbers of financially independent, older or single women who choose to have children on their own (Washington Post, 5/14). Researchers noted that most of the increase in these births was among parents who live together but are not married (New York Times, 5/13)."I think this is the tipping point," Rosanna Hertz of Wellesley College said, adding, "This is becoming increasingly the norm. The old adage that "first comes love, then comes marriage, then comes baby in the baby carriage" just no longer holds true." Hertz added, "Women can have children on their own, and it"s not going to destroy your employment, and it"s not going to mean that you"ll be made a pariah by the community. It"s much more socially acceptable." Sarah Brown of the National Campaign To Prevent Teen and Unplanned Pregnancy said, "I look at this and say, maybe this trend is what young adults want or stumble into, but it"s not in the best interest of children" (Washington Post, 5/14).
News of the day
Antiabortion-Rights Group Operation Rescue Considering Purchase Of Tiller's Clinic
Operation Rescue President Troy Newman on Wednesday said that his group is considering trying to purchase murdered abortion provider George Tiller"s Wichita, Kan., clinic, which Tiller"s family permanently closed on Tuesday, the New York Times reports. The clinic is owned by Tiller"s family. The family"s lawyer, Dan Monnat, called Operation Rescue"s proposal "just another irreverent, extremist publicity stunt." He declined to comment further on the situation. The family has not announced its plans for the building and land, which are worth $734,100, according to Sedgwick County, Kan., property records. The clinic has long been a focal point for the antiabortion-rights movement because it was one of the few in the U.S. that offered abortion later in pregnancy. Newman said that he has discussed the possible purchase with only a few members of Operation Rescue"s board but is certain that the funds could be raised if they decide to attempt to buy the clinic. Newman also said that one possibility for the location would be to turn it into a memorial museum to serve as "a tribute to the babies." He denied the claim that his comments are a publicity stunt.According to the Times, the closing of Tiller"s clinic has set off a "flurry of concerns" from abortion-rights advocates that it will be more difficult for women to access abortion services in situations when catastrophic health issues are identified late in pregnancy (Davey, New York Times, 6/11). LeRoy Carhart, a Nebraska abortion provider who worked with Tiller at the clinic, said that he will continue to perform third-trimester abortions in Kansas but did not provide information on where he will practice, the AP/Yahoo! News reports. Although he did not provide details, Carhart said that "there will be a place in Kansas for the later second- and the medically indicated third-trimester patients very soon." He said he has seen an increase in patients at his Nebraska clinic since Tiller"s murder. Carhart traveled to Tiller"s clinic to perform second- and third-trimester abortions because Kansas has less restrictive abortion laws than Nebraska. Carhart said he has not performed any procedures at his clinic after 22 weeks" gestation because his staff is not trained to do them. According to the AP/Yahoo! News, Nebraska law prohibits abortion when a fetus is considered viable. Kansas law, however, allows abortion after 21 weeks" gestation if continuing the pregnancy would endanger the woman"s life or cause "substantial and irreversible impairment" of a major bodily function, which courts have interpreted to include mental health (Gibbs, AP/Yahoo! News, 6/11).Broadcast CoverageThree media outlets on Wednesday reported on issues related to Tiller"s murder. Summaries appear below.~ MSNBC"s "The Rachel Maddow Show": The program included a discussion with Jennifer Boulanger, executive director for the Allentown Women"s Center, about threats to the center since Tiller"s murder (Maddow, "The Rachel Maddow Show," MSNBC, 6/10).~ NPR"s "All Things Considered": The program included a discussion with NPR health policy correspondent Julie Rovner about the correct terminology for referring to abortion later in pregnancy and why the phrase "late-term abortion" is inaccurate (Block, "All Things Considered," NPR, 6/10).~ WBUR"s "On Point": The program included a discussion with the Rev. Katherine Ragsdale -- a board member of NARAL Pro-Choice America and the incoming dean and president of Episcopal Divinity School -- and Jim Wallis -- founder and editor of the progressive evangelical group Sojourners -- about abortion-rights supporters" reaction to violence in the antiabortion-rights movement (Ashbrook, "On Point," WBUR, 6/10).
Diagnostics

Wyeth Reports Publication Of Phase 3 Data For Bazedoxifene/Conjugated Estrogens

Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced the publication in Fertility and Sterility of data from a Phase 3 clinical study that showed that the investigational compound bazedoxifene/conjugated estrogens (BZA/CE) significantly reduced the frequency and severity of hot flushes and improved measures of vaginal atrophy when compared to placebo. In this study, uterine bleeding was not statistically different from placebo and the rate of endometrial hyperplasia in doses being considered for therapeutic use was Fertility and Sterility, is from the Selective estrogens Menopause And Response to Therapy (SMART-1) clinical trial. SMART-1 was designed to explore the hypothesis that bazedoxifene, when paired with conjugated estrogens, may have the potential to eliminate the need for progestin in menopausal therapy in women with an intact uterus. BZA/CE is characterized by Wyeth as a TSEC (tissue selective estrogen complex) as it combines a selective estrogen receptor modulator (SERM) with conjugated estrogens. Across the SMART-1 trial, the incidence of treatment-emergent adverse events, breast pain, serious adverse events and withdrawals due to adverse events were similar among the active treatment groups and placebo. About SMART-1 SMART-1 was a two-year, multinational, multicenter, randomized, double-blind, placebo- and active-controlled Phase 3 study that evaluated 3,397 healthy, postmenopausal women with an intact uterus aged 40 to 75 years. The primary end point of the SMART-1 trial was incidence of endometrial hyperplasia at one year. Secondary end points included bone mineral density (BMD) at two years, menopausal vasomotor symptoms at four and 12 weeks, vaginal maturation index at six months, menopause-related quality of life measures, and overall safety and tolerability. Titles and Summary of Findings From Published Manuscripts 1. Endometrial Protection in Menopausal Therapy with a Tissue Selective Estrogen Complex (TSEC) Containing Bazedoxifene/Conjugated Estrogens (Pickar JH, et al) To evaluate endometrial effects, biopsies were performed at screening and at months six, 12, and 24, or when subjects withdrew from the study and more than three months had elapsed since their last assessment. Treatment with BZA/CE doses being considered for therapeutic use were associated with rates of endometrial hyperplasia 2. Bazedoxifene/Conjugated Estrogens (BZA/CE): Incidence of Uterine Bleeding in Postmenopausal Women (Archer DF, et al) To evaluate the effect of treatment with BZA/CE on uterine bleeding, trial participants were asked to record in a diary whether or not they experienced bleeding and/or spotting. The mean number of bleeding or spotting days with BZA/CE was not statistically different from placebo over two years of therapy. 3. Evaluation of Bazedoxifene/Conjugated Estrogens (BZA/CE) for the Treatment of Menopausal Symptoms and Effects on Metabolic Parameters and Overall Safety Profile (Lobo R, et al) Results from a sub-analysis suggest that treatment with BZA/CE significantly reduced the frequency and severity of hot flushes and improved measures of vaginal atrophy compared with placebo. In this study, analysis of most clinical laboratory determinations revealed no clinically important differences among treatment groups and no trends of concern. The incidences of breast pain and adverse events were similar between BZA/CE and placebo. 4. Efficacy of Tissue-Selective Estrogen Complex (TSEC) of Bazedoxifene/Conjugated Estrogens (BZA/CE) for Osteoporosis Prevention in At-Risk Postmenopausal Women (Lindsay R, et al) When compared with placebo, treatment with BZA/CE increased BMD at the lumbar spine and total hip at 24 months. These results suggest that women in the BZA/CE groups gained bone mass while women in the placebo treatment group lost BMD. About Menopause Approximately 40 million women in the United States are of menopausal age (45 to 64 years). Of these women, 17 million experience vasomotor symptoms; 9 million experience moderate to severe symptoms. Menopause is different for every woman, and vasomotor symptoms can last from a few months to many years and they can be mild, moderate or severe enough to interfere with daily life. The majority of menopausal women experiencing moderate to severe vasomotor symptoms are not currently treating their symptoms. About Fertility and Sterility Fertility and Sterility is the official publication of the American Society of Reproductive Medicine, which publishes peer-reviewed original articles of research relevant to reproductive endocrinology, physiology, immunology, genetics and menopause. About Wyeth Pharmaceuticals Wyeth Pharmaceuticals has leading products in the areas of women"s health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products. Wyeth is one of the world"s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company"s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health. The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, clinical trial data are subject to differing interpretations, and the views of regulatory agencies, medical and scientific experts and others may differ from ours or those expressed in the referenced publication. The Phase 3 clinical trial data presented and published to date reflect only a portion of the totality of data available from Phase 3 studies of BZA/CE and, accordingly, do not represent the totality of data and other information that may affect regulatory review and commercialization of BZA/CE. There can be no assurance that BZA/CE will ever receive regulatory approval or be successfully developed and commercialized. Other risks and uncertainties include, among others, risks related to our proposed merger with Pfizer, including satisfaction of the conditions of the proposed merger on the proposed timeframe or at all, contractual restrictions on the conduct of our business included in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; the outcome of government investigations; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; global economic conditions; interest and currency exchange rate fluctuations and volatility in the credit and financial markets; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on February 27, 2009. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. Wyeth


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009